Gottlieb Defends FDA’s Approach to New Opioids After Dsuvia Approval

Drug Industry Daily
FDA Commissioner Scott Gottlieb defended the FDA’s approval of a powerful opioid that critics say is more addictive and susceptible to diversion than fentanyl — and said the agency plans to consider the merits of any new drug along with efforts to address the opioid epidemic.

To View This Article:


Subscribe To Drug Industry Daily